Literature DB >> 22477828

Respiratory syncytial virus pathophysiology and affect of palivizumab in special populations: cystic fibrosis and immunosuppression.

Michael E Speer1.   

Abstract

Entities:  

Year:  2011        PMID： 22477828      PMCID： PMC3208443          DOI： 10.5863/1551-6776-16.2.74

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN： 1551-6776


× No keyword cloud information.
  32 in total

1.  Respiratory syncytial virus inhibits granulocyte apoptosis through a phosphatidylinositol 3-kinase and NF-kappaB-dependent mechanism.

Authors:  Caroline A Lindemans; Paul J Coffer; Ingrid M M Schellens; Patricia M A de Graaff; Jan L L Kimpen; Leo Koenderman
Journal:  J Immunol       Date:  2006-05-01       Impact factor: 5.422

2.  Respiratory syncytial virus influences NF-kappaB-dependent gene expression through a novel pathway involving MAP3K14/NIK expression and nuclear complex formation with NF-kappaB2.

Authors:  Sanjeev Choudhary; Steve Boldogh; Roberto Garofalo; Mohammad Jamaluddin; Allan R Brasier
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

3.  Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency.

Authors:  Asunción Mejías; Susana Chávez-Bueno; Ana María Ríos; Mónica Fonseca Aten; Brett Raynor; Estrella Peromingo; Perla Soni; Kurt D Olsen; Peter A Kiener; Ana María Gómez; Hasan S Jafri; Octavio Ramilo
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

4.  Respiratory syncytial virus infections in pediatric renal transplant recipients.

Authors:  R B Miller; B M Chavers
Journal:  Pediatr Nephrol       Date:  1996-04       Impact factor: 3.714

5.  Palivizumab is highly effective in suppressing respiratory syncytial virus in an immunosuppressed animal model.

Authors:  M G Ottolini; S R Curtis; A Mathews; S R Ottolini; G A Prince
Journal:  Bone Marrow Transplant       Date:  2002-01       Impact factor: 5.483

6.  Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis.

Authors:  P W Hiatt; S C Grace; C A Kozinetz; S H Raboudi; D G Treece; L H Taber; P A Piedra
Journal:  Pediatrics       Date:  1999-03       Impact factor: 7.124

7.  Effect of respiratory virus infections including rhinovirus on clinical status in cystic fibrosis.

Authors:  A R Smyth; R L Smyth; C Y Tong; C A Hart; D P Heaf
Journal:  Arch Dis Child       Date:  1995-08       Impact factor: 3.791

8.  Association of respiratory viral infections with pulmonary deterioration in patients with cystic fibrosis.

Authors:  E E Wang; C G Prober; B Manson; M Corey; H Levison
Journal:  N Engl J Med       Date:  1984-12-27       Impact factor: 91.245

9.  Respiratory syncytial virus infection in a murine model of cystic fibrosis.

Authors:  Giuseppe N Colasurdo; Jason J Fullmer; Okan Elidemir; Constance Atkins; Amir M Khan; James M Stark
Journal:  J Med Virol       Date:  2006-05       Impact factor: 2.327

10.  Increased pathogenesis and inflammation of airways from respiratory syncytial virus infection in T cell deficient nude mice.

Authors:  Juan Zhou; Xi-Qiang Yang; Zhou Fu; Xiao-Dong Zhao; Li-Ping Jiang; Li-Jia Wang; Yu-Xia Cui
Journal:  Med Microbiol Immunol       Date:  2007-12-05       Impact factor: 3.402
View more
  1 in total

1.  Impaired gamma delta T cell-derived IL-17A and inflammasome activation during early respiratory syncytial virus infection in infants.

Authors:  Huaqiong Huang; Jordy Saravia; Dahui You; Aaron J Shaw; Stephania A Cormier
Journal:  Immunol Cell Biol       Date:  2014-09-30       Impact factor: 5.126
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.